Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer

• Status: Terminated
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and effectiveness of the combination of oxaliplatin and irinotecan (CPT-11) in patients with previously untreated, advanced small cell lung cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Swedish Medical Center
• Collaborator: Sanofi-Synthelabo
• Treatments: Irinotecan; Oxaliplatin

Criteria

Inclusion Criteria:

• Previously untreated extensive small cell lung cancer

• No prior chemotherapy

• No prior radiotherapy except for the treatment of brain metastases

Exclusion Criteria:

• Prior treatment for extensive stage small cell lung cancer

• Known hypersensitivity to any of the components of oxaliplatin or CPT-11

• Greater than grade 2 peripheral neuropathy

• Known HIV or Hepatitis B or C (active, previously treated or both)